基本信息

       胡劲松,男,副教授,博士研究生导师。博士毕业于第四军医大学(2009年, 细胞生物学专业)、布鲁塞尔自由大学(2012年, 医学博士)。目前任职于西安交通大学医学部基础医学院细胞生物学与遗传学系。曾担任西安交通大学医学部基础医学院细胞生物学与遗传学系副系主任(主持工作,2015年4月-2019年4月)。现任基础医学实验教学中心副主任。

       美国血液学会会员; 欧洲血液学会会员; 比利时血液学会会员; 中国细胞生物学会会员。

       学术兼职:中华医学会医学细胞生物学分会第六届委员会委员 2018年)

                         中国抗癌协会肿瘤分子医学专业委员会第一届委员(2017年)

                         中国肿瘤防治联盟陕西省淋巴瘤专业委员会委员(2017年)

                         陕西省细胞生物学学会第四届理事会常务理事(2018年)

                         中国肿瘤防治联盟陕西省淋巴瘤专业委员会第一届委员(2017年)

                         中国多发性骨髓瘤研究联盟理事(2018年)

                        中国抗癌协会第五届血液肿瘤专业委员会骨髓瘤与浆细胞疾病学组委员 2019年)

                         中国医药教育协会-智能医学专业委员会常委(2019

                         中国转化医学联盟细胞生物学分会第一届委员(2019

       中组部第7批援疆(挂职)干部,曾任新疆维吾尔医学专科学校教务处副处长(挂职)。并被新疆自治区授予二等功。

      

       联系方式:  E-mail:jinsong.hu@xjtu.edu.cn

 

 

科学研究与研究生教育

 研究领域:血液肿瘤细胞分子生物学、肿瘤免疫

 研究方向:(1)多发性骨髓瘤、淋巴瘤的细胞与分子病理机制、耐药分子机制。

                   (2)干细胞及其成骨分化分化机制研究。

                   (3)基因工程改造NK细胞治疗恶性血液系肿瘤。

研究生招生: 欢迎医学(含动物医学)、生物学等专业学生报考。具体招生信息请参阅当年简章或邮件与导师联系。

研究生提供严谨、科学、自由、奋进的科学研究氛围;与美国哈佛大学医学院Dana-Farber Cancer Institute、比利时布鲁塞尔自由学、法国nantes大学、爱尔兰国立大学医学院、德国国家癌症中心(NCI)、法国里尔大学附属医院等著名机构有深入合作关系,能为研究生提供一流的出国学习、合作研究机会。

科研项目:(1)国家自然科学基金项目2项。 (2)中-爱国际合作横向科研项目1项。(3)西安交大医学部-秦农银行COVID-19专项(重点)

Publications (# first author, * corresponding author)

1.      Zhang D#, Guo R#, Lei L#, Liu H#, Wang Y, Wang Y, Qian H, Dai T, Zhang T, Lai Y, Wang J, Liu Z, Chen T, He A*, O'Dwyer M*, Hu J*. COVID-19 infection induces readily detectable morphologic and inflammation-related phenotypic changes in peripheral blood monocytes. J Leukoc Biol. 2020 Oct 11. doi: 10.1002/JLB.4HI0720-470R.

2.      Lei L#, Qian H#, Yang X, Zhang X, Zhang D, Dai T, Guo R, Shi L, Cheng Y, Zhang B, Zhou X*, Hu J*, Guo Y*. The phenotypic changes of γδ T cells in COVID-19 patients. J Cell Mol Med. 2020 Aug 30. doi: 10.1111/jcmm.15620.

3.      Yang X#, Dai T#, Zhou X, Qian H, Guo R, Lei L, Zhang X, Zhang D, Shi L, Cheng Y, Hu J*, Guo Y*, Zhang B*. Naturally activated adaptive immunity in COVID-19 patients. J Cell Mol Med. 2020 Sep 25. doi: 10.1111/jcmm.15771.

4.      Teng R#, Wang Y#, Nan Lv, Zhang D, Williamson RA, Lei L, Chen P, Lei L, Wang B, Fu J, Liu X, He A, O’Dwyer M*, Hu J*. Hypoxia Impairs NK Cell Cytotoxicity through SHP-1-Mediated Attenuation of STAT3 and ERK Signaling Pathways. Journal of Immunology Research. Pub Date : 2020-06-19 , DOI: 10.1155/2020/4598476.

5.      Zhang D#, Teng R#, Lv N, Lei L, Wang Y, Williamson RA, Chen P, Gao P, O'Dwyer M, Li A*, Hu J*. A novel CD2 staining-based flow cytometric assay for assessment of natural killer cell cytotoxicity. J Clin Lab Anal. 2020 Aug 17:e23519. doi: 10.1002/jcla.23519.

6.      Zhang D#, Fan R#, Lei L, Lei L, Wang Y, Lv N, Chen P, Williamson RA, Wang B, Hu J*. Cell cycle exit during bortezomib-induced osteogenic differentiation of mesenchymal stem cells was mediated by Xbp1s-upregulated p21Cip1 and p27Kip1. J Cell Mol Med. 2020 Jul 6;24(16):9428–38. doi: 10.1111/jcmm.15605.

7.      Peng Y#, Li F, Zhang P, Wang X, Shen Y, Feng Y, Jia Y, Zhang R, Hu J*, He A*. IGF-1 promotes multiple myeloma progression through PI3K/Akt-mediated epithelial-mesenchymal transition. Life Sci. 2020 Mar 3;249:117503. doi: 10.1016/j.lfs.2020.117503.

8.      Huang L#, Wang Y, Bai J, Yang Y, Wang F, Feng Y, Zhang R, Li F, Zhang P, Lv N, Lei L, Hu J*, He A*. Blockade of HSP70 by VER-155008 synergistically enhances bortezomib-induced cytotoxicity in multiple myeloma. Cell Stress Chaperones. 2020 Mar;25(2):357-367.

9.      Huang LJ#, Shen Y, Bai J, Wang FX, Feng YD, Chen HL, Peng Y, Zhang R, Li FM, Zhang PH, Lei XR, Xue F, Ma YP, Hu JS*, He AL*. High Expression Levels of Long Noncoding RNA Small Nucleolar RNA Host Gene 18 and Semaphorin 5A Indicate Poor Prognosis in Multiple Myeloma. Acta Haematol. 2019 Oct 9.1-10.

10.   Jia X#, Zhao Q, Zhang Y, Dong Y, Lei L, Williamson RA, Lei Y, Tan X, Zhang D*, Hu J*. Identification of a Five-CpG Signature with Diagnostic Value in Thyroid Cancer. J Comput Biol. 2019;26(12):1409-1417.

11.   Zhang D#, Cui G#, Sun C, Lei L, Lei L, Williamson RA, Wang Y, Zhang J, Chen P, Wang A, Fan R, Han S, Wang Y*, Hu J*. Hypoxia promotes osteosarcoma cell proliferation and migration through enhancing platelet-derived growth factor-BB/platelet-derived growth factor receptor-β axis. Biochem Biophys Res Commun. 2019;512(2):360-366.

12.   Zhu M#Tian YZhang HMa XShang BZhang JJiao YZhang YHu JWang Y. Methylphenidate ameliorates hypoxia-induced mitochondrial damage in human neuroblastoma SH-SY5Y cells through inhibition of oxidative stress. Life Sci. 2018 Mar 15;197:40-45. doi: 10.1016/j.lfs.2018.01.027.

13.   Hu J#, Van Valckenborgh E, Dehui X, Menu E, De Raeve H, De Bruyne E, Xu S, Van Camp B, Handisides D, Hart CP, Vanderkerken K. Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro. Mol Cancer Ther. 2013;12(9):1763-1773.   

14.   Hu J#, Van Valckenborgh E, Menu E, De Bruyne E, Vanderkerken K. Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models. Dis Model Mech. 2012;5(6):763-71.            

15.   Hu J#, Dang N, Menu E, De Bryune E, Xu D, Van Camp B, Van Valckenborgh E, Vanderkerken K. Activation of ATF4 mediates unwanted Mcl-1 accumulation by proteasome inhibition. Blood. 2012;119(3):826-37. IF>10   

16.   Hu J#, Dang N, Song T, Vanderkerken K. Mcl-1 reduction due to caspase-dependent cleavage during endoplasmic reticulum stress-induced apoptosis. J Biol Chem. 2011;286(44):le24.  

17.   Hu J#, Handisides DR, Van Valckenborgh E, De Raeve H, Menu E, Vande Broek I, Liu Q, Sun JD, Van Camp B, Hart CP, Vanderkerken K. Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug. Blood. 2010;116(9):1524-7.  IF>10   

18.   Hu J#, Dang N#, Yao H, Li Y, Zhang H, Yang X, Xu J, Bian H, Xing J, Zhu P, Chen Z. Involvement of HAb18G/CD147 in T cell activation and immunological synapse formation. J Cell Mol Med. 2010;14(8):2132-43.  

19.   Dang N#, Hu J#, Liu X, Li X, Ji S, Zhang W, Su J, Lu F, Yang A, Han H, Han W, Jin B, Yao L.        CD167 acts as a novel costimulatory receptor in T-cell activation. J Immunother.         2009;32(8):773-84. 

20.   Xu D#, Hu J, Xu S, De Bruyne E, Menu E, Van Camp B, Vanderkerken K, Van Valckenborgh E. Dll1/Notch activation accelerates multiple myeloma disease development by promoting CD138+ MM-cell proliferation. Leukemia. 2012;26(6):1402-5.    (IF>10)    

21.   Azab AK#, Hu J, Quang P, Azab F, Pitsillides C, Awwad R, hompson B, Maiso P, Sun JD, Hart CP, Roccaro AM, acco A, Ngo HT, Lin CP, Kung AL, Carrasco DR, Vanderkerken K, Ghobrial IM. Hypoxia promotes dissemination of multiple myeloma through acquisition of endothelial to mesenchymal transition-like features. Blood. 2012;119(24):5782-94.   (IF=>10)  

22.   Xu D#, Hu J, Bruyne ED, Menu E, Schots R, Vanderkerken K, Van Valckenborgh E. Dll1/Notch activation contributes to bortezomib resistance by upregulating CYP1A1 in multiple myeloma. Biochem Biophys Res Commun. 2012;428(4):518-24.    

23.   Xu S#, Evans H, Buckle C, De Veirman K, Hu J, Xu D, Menu E, De Becker A, Vande Broek I, Leleu X, Camp BV, Croucher P, Vanderkerken K, Van Riet I. Impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients is associated with a blockade in the deactivation of the Notch signaling pathway. Leukemia. 2012;26(12):2546-9.  (IF>10)

24.   Wang H#*, Lei L#, Hu J, Li Y. Oncostatin M upregulates Livin to promote keratinocyte proliferation and survival via ERK and STAT3 signalling pathways. Exp Physiol. 2020 Jul;105(7):1151-1158. doi: 10.1113/EP088584.

25.   Sarkar S#, Chauhan SKS, Daly J, Natoni A, Fairfield H, Henderson R, Nolan E, Swan D, Hu J, Reagan MR, O'Dwyer M. The CD38low natural killer cell line KHYG1 transiently expressing CD16F158V in combination with daratumumab targets multiple myeloma cells with minimal effector NK cell fratricide. Cancer Immunol Immunother.2020 Mar;69(3):421-434. doi: 10.1007/s00262-019-02477-8.

专利
 1.  获批PCT国际专利1项(WO2018/104554A1):Improved NK based cell therapy (2018年)
 

 

站点计数器